On April 13, 2022, ICER released its draft evidence report, “Betibeglogene Autotemcel for Beta Thalassemia.” This document provides a framework for considering what aspects of betibeglogene autotemcel (beti-cel) – a potential curative new gene therapy for beta thalassemia – are important to patients and their families, and how to consider presenting those perspectives. This guide specifically provides insights about how to read and respond to ICER’s draft evidence report, as well as how to request a slot to make comments during ICER’s public meeting.
Key Dates
| April 13, 2022: | Draft Evidence Report released |
| May 10, 2022: | Written comments due by 5:00pm ET; deadline to submit request to speak at Public Meeting |
| June 2, 2022: | Updated Evidence Report released |
| June 17, 2022: | Public Meeting conducted by ICER’s New England Comparative Effectiveness Public Advisory Council (CEPAC) |
| July 19, 2022: | Final Evidence Report and Public Meeting Summary released |
Take Action Today!
Everything you need is in the guide.
